14.94

2.61% -0.40

After Hours: 15.06 0.12 +0.80%

Cullinan Therapeutics Inc (CGEM)

Overview News Price History Option Chain Financials Discussions Forecast

Cullinan Therapeutics Inc stock is traded at $14.94, with a volume of 893.20K. It is down -2.61% in the last 24 hours and up +3.53% over the past month. Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Previous Close:

$15.34

Open:

$15.48

24h Volume:

893.20K

Relative Volume:

1.11

Market Cap:

$918.08M

Revenue:

Net Income/Loss:

$-219.88M

P/E Ratio:

-4.012

EPS:

-3.7238

Net Cash Flow:

$-175.76M

1W Performance:

+16.63%

1M Performance:

+3.53%

6M Performance:

+104.38%

1Y Performance:

+80.65%

1-Day Range:

$14.21

$15.75

1-Week Range:

$12.42

$15.90

52-Week Range:

$5.68

$16.74

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name

Cullinan Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

617-410-4650

Address

ONE MAIN STREET, CAMBRIDGE

Employee

109

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

CGEM's Discussions on Twitter

Compare CGEM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEM Cullinan Therapeutics Inc	14.94	942.66M	0	-219.88M	-175.76M	-3.7238
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Initiated	Citigroup	Buy
Feb-02-26	Initiated	Guggenheim	Buy
Aug-21-25	Resumed	H.C. Wainwright	Buy
Jun-11-25	Resumed	Stifel	Buy
Oct-24-24	Initiated	UBS	Buy
May-01-24	Initiated	Stifel	Buy
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-02-21	Initiated	Evercore ISI	Outperform
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight
Feb-02-21	Initiated	SVB Leerink	Outperform
Feb-01-21	Initiated	H.C. Wainwright	Buy

View All

Cullinan Therapeutics Inc Stock (CGEM) Latest News

05:25 AM

Insider sales at CGEM (NASDAQ: CGEM) include 8,000-share 10b5-1 trade - Stock Titan

05:25 AM

01:30 AM

Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6%Time to Sell? - MarketBeat

01:30 AM

02:51 AM

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

02:51 AM

May 04, 2026

CGEM Reiterates by BTIG -- Price Target Maintained at $38.00 - GuruFocus

May 04, 2026

Cullinan Therapeutics (NASDAQ:CGEM) Trading 8.5% HigherHere's Why - MarketBeat

May 04, 2026

Cullinan Therapeutics (NASDAQ:CGEM) Receives "Buy" Rating from BTIG Research - MarketBeat

May 04, 2026

May 03, 2026

Cullinan Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Michaelson Jennifer - Moomoo

May 03, 2026

May 02, 2026

Cullinan wins FDA review for cancer therapy developed with Taiho - MSN

May 02, 2026

Apr 30, 2026

Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst (NASDAQ:CGEM) - Seeking Alpha

Apr 30, 2026

H.C. Wainwright Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Apr 30, 2026

Research Analysts Issue Forecasts for CGEM Q1 Earnings - MarketBeat

Apr 30, 2026

Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

Wedbush Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $36 - Moomoo

Apr 29, 2026

A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $38 - Moomoo

Apr 29, 2026

Cullinan Therapeutics' (CGEM) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat

Apr 29, 2026

Apr 28, 2026

CGEM Maintained by HC Wainwright & Co. -- Price Target Raised to $30 - GuruFocus

Apr 28, 2026

HC Wainwright Forecasts Strong Price Appreciation for Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat

Apr 28, 2026

Cullinan Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers - Moomoo

Apr 28, 2026

Cullinan Therapeutics (NASDAQ: CGEM) launches $200M ATM with TD Cowen - Stock Titan

Apr 28, 2026

Cullinan Therapeutics NDA for zipalertinib in advanced NSCLC accepted by FDA - Traders Union

Apr 28, 2026

Cullinan Therapeutics | ARS: Annual Report to Security Holders - Moomoo

Apr 28, 2026

Cullinan Therapeutics | DEF 14A: Definitive information statements - Moomoo

Apr 28, 2026

Cullinan Therapeutics | DEFA14A: Others - Moomoo

Apr 28, 2026

FDA starts review of new lung cancer drug, decision due Feb. 2027 - Stock Titan

Apr 28, 2026

Cullinan Therapeutics (CGEM) outlines 2026 virtual annual meeting - Stock Titan

Apr 28, 2026

Apr 27, 2026

Cullinan Therapeutics (NASDAQ:CGEM) Trading 6.2% HigherStill a Buy? - MarketBeat

Apr 27, 2026

Apr 23, 2026

We're Hopeful That Cullinan Therapeutics (NASDAQ:CGEM) Will Use Its Cash Wisely - Sahm

Apr 23, 2026

Apr 19, 2026

Cullinan Therapeutics (CGEM): Wedbush Raises Price Target to $36 - GuruFocus

Apr 19, 2026

Apr 18, 2026

Is Cullinan (CGEM) stock showing weakness (+2.17%) 2026-04-18Professional Trade Ideas - Xã Châu Thành

Apr 18, 2026

Apr 17, 2026